Edgewise Initiates ARCH Follow-On Open Label Becker Study; Will Report Phase 1b Topline Results on January 5
Edgewise Therapeutics has announced the initiation of the ARCH open label study of EDG-5506 in Becker muscular dystrophy, which will enroll participants from its Phase 1b clinical trial as well as new participants with Becker….Learn More